Summer is almost over. If you haven’t planned Fall advertising, you’re late! Let us do it. We handle everything. Talk to Undine McEvoy, firstname.lastname@example.org.
Webinars are a great marketing tools, but they can be a hassle…Not anymore. We do it all. HealthEconomics.Coms Webinar & Podcast Package, ask about it today. Contact Undine@healtheconomics.com.
|IN THIS ISSUE|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|Stratifying High-Risk, High-Cost Patients|
Healthcare organizations employ a variety of tools and analytics to identify high-risk, high-cost patients for targeted population health interventions. This report presents a range of risk stratification practices to determine candidates for health coaching, case management, home visits, remote monitoring and other initiatives designed to engage individuals with chronic illness, improve health outcomes and reduce healthcare spend. (Source: Healthcare Intelligence Network, August 2014).
What is Hepatitis C? What percentage of specialty pharmaceuticals require in-office administration? Are patients actively involved in reporting adherence? Is early detection helping? The answers to these questions and more, available in this specialty pharmacy trends report from First Report Managed Care. (Source: First Report Managed Care, 7/23/14).
Many speculated, after a request for more data, that the National Institute for Health and Care Excellence (NICE) would not be recommending Sovaldi, but after reviewing the data, NICE concluded that Sovaldi is an effective improvement over existing treatments. So what made NICE approve a drug that has been so controversial in other countries around the world? (Source: Ed Silverman, The Wall Street Journal, 8/14/14).
Are Cancer drug prices a reflection of the rising costs of drug development and business risks, or are they a reflection of the industry’s greed- charging whatever they think they can get away with? This article takes a look at the latest new drug for lung cancer, Novartis’ Zykadia, and its older competitor, Pfizer’s Xalkori, and tries to make sense of the price difference. (Source: Matthew Herper, Forbes, 8/13/14).
Pharmaceutical companies must understand how the evidential requirements of regulators and payers differ and that it is a must to gain early insights into the needs of payers in order to develop the evidence and value messages that match their needs. This article provides a short introduction into Market Access and some of the tactical approaches that can help to optimize the opportunity for new products. (Source: Steven Bradshaw, Pharma iQ, 8/13/14).
According to a 2013 report, only 14% of Americans understand basic insurance concepts such as deductible, copay, coinsurance and out-of-pocket-maximum. In an effort to help consumers make informed decisions to maximize their health benefits plan, it is increasingly important for health plans to provide educational resources and tools. Most insurance carriers have mobile apps allowing users 24/7 access to registered nurses, the ability to locate nearby in-network physician or hospital, and access to personal health benefits information. Tools like UnitedHealthcare’s myHealthcare Cost Estimator (myHCE) provide cost and quality information of local care providers for more than 500 common medical services. Have you taken the time to log on to your insurance provider’s website to learn more about the tools and services available to you? (Source: Gregory Reidy, The Tennessean, 8/12/14).
The FDA has recently issued an updated guidance document on obtaining informed consent for clinical trials. The majority of the document content appears to remain unchanged, specifying in greater detail how consent should be obtained. The one exception being a section urging that trial participants be told the outcome of the trial. (Source: Joyce Frieden, medpage Today, 7/22/14).
Are you writing a manuscript on health policy analysis, original health care research, or other health-related topics focusing on Asia, Latin America, or Central & Eastern Europe, Western Asia and Africa (CEEWAA)? If so, ISPOR invites you to submit your manuscript(s) for consideration in ISPOR’s region-specific scientific peer-reviewed journal, Value in Health Regional Issues (ViHRI). Value in Health Regional Issues submission and editorial review process is year-round. To be considered for the following upcoming issues, you are encouraged to submit your manuscript(s). (Source: ISPOR, 2014).
In an effort to better connect with consumers in a radically changing healthcare system and eliminate brand confusion, WellPoint is looking to rebrand itself as Anthem. This move is pending shareholder approval, but is believed to go into effect by the end of 2014. (Source: Bob Herman, Modern Healthcare, 8/12/14).
The demands on market access teams are growing rapidly as the specific needs of key stakeholders grow ever greater. How do you structure a market access team, what is its role and how can you assess its success? FirstWord helps you find answers to these questions and more in this article, Market Access Team Management: Driving Exceptional Performance. Article available for purchase. (Source: FirstWord, 8/2014).
|Link of the Week||Conference of the Week||Webinar of the Week|